168 related articles for article (PubMed ID: 9021525)
1. Effects of treatment with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor antagonist (AIIRA) on renal function and glomerular injury in subtotal nephrectomized rats.
Yamamoto M; Fukui M; Shou I; Wang LN; Sekizuka K; Suzuki S; Shirato I; Tomino Y
J Clin Lab Anal; 1997; 11(1):53-62. PubMed ID: 9021525
[TBL] [Abstract][Full Text] [Related]
2. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure.
Kakinuma Y; Kawamura T; Bills T; Yoshioka T; Ichikawa I; Fogo A
Kidney Int; 1992 Jul; 42(1):46-55. PubMed ID: 1635354
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.
Lafayette RA; Mayer G; Park SK; Meyer TW
J Clin Invest; 1992 Sep; 90(3):766-71. PubMed ID: 1522231
[TBL] [Abstract][Full Text] [Related]
4. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
Oikawa T; Freeman M; Lo W; Vaughan DE; Fogo A
Kidney Int; 1997 Jan; 51(1):164-72. PubMed ID: 8995730
[TBL] [Abstract][Full Text] [Related]
5. The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice.
Peten EP; Striker LJ; Fogo A; Ichikawa I; Patel A; Striker GE
Mol Med; 1994 Nov; 1(1):104-15. PubMed ID: 8790606
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
Lebel M; Rodrigue ME; Agharazii M; Larivière R
Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
[TBL] [Abstract][Full Text] [Related]
7. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
Noda M; Fukuda R; Matsuo T; Ohta M; Nagano H; Imura Y; Nishikawa K; Shibouta Y
Kidney Int Suppl; 1997 Dec; 63():S136-9. PubMed ID: 9407442
[TBL] [Abstract][Full Text] [Related]
8. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR.
Zhou X; Matavelli LC; Ono H; Frohlich ED
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F871-9. PubMed ID: 15900021
[TBL] [Abstract][Full Text] [Related]
9. Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats.
Fabris B; Candido R; Armini L; Fischetti F; Calci M; Bardelli M; Fazio M; Campanacci L; Carretta R
J Hypertens; 1999 Dec; 17(12 Pt 2):1925-31. PubMed ID: 10703891
[TBL] [Abstract][Full Text] [Related]
10. The effect of enalapril on glomerular growth and glomerular lesions after subtotal nephrectomy in the rat: a stereological analysis.
Amann K; Irzyniec T; Mall G; Ritz E
J Hypertens; 1993 Sep; 11(9):969-75. PubMed ID: 8254179
[TBL] [Abstract][Full Text] [Related]
11. Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats.
Sugimoto K; Tsuruoka S; Matsushita K; Fujimura A
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S63-70; discussion S81. PubMed ID: 10076923
[TBL] [Abstract][Full Text] [Related]
12. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach.
Zoja C; Corna D; Camozzi D; Cattaneo D; Rottoli D; Batani C; Zanchi C; Abbate M; Remuzzi G
J Am Soc Nephrol; 2002 Dec; 13(12):2898-908. PubMed ID: 12444208
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model.
Raij L; Chiou XC; Owens R; Wrigley B
Am J Med; 1985 Sep; 79(3C):37-41. PubMed ID: 2996345
[TBL] [Abstract][Full Text] [Related]
14. Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature.
Adamczak M; Gross ML; Amann K; Ritz E
J Am Soc Nephrol; 2004 Dec; 15(12):3063-72. PubMed ID: 15579509
[TBL] [Abstract][Full Text] [Related]
15. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.
Ziai F; Ots M; Provoost AP; Troy JL; Rennke HG; Brenner BM; Mackenzie HS
Kidney Int Suppl; 1996 Dec; 57():S132-6. PubMed ID: 8941934
[TBL] [Abstract][Full Text] [Related]
16. Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.
Zhou A; Yu L; Li J; Zhang J; Wang H
Hypertens Res; 2000 Jul; 23(4):391-7. PubMed ID: 10912779
[TBL] [Abstract][Full Text] [Related]
17. Renin-angiotensin system blockade alone or combined with ET
Sedláková L; Čertíková Chábová V; Doleželová Š; Škaroupková P; Kopkan L; Husková Z; Červenková L; Kikerlová S; Vaněčková I; Sadowski J; Kompanowska-Jezierska E; Kujal P; Kramer HJ; Červenka L
Clin Exp Hypertens; 2017; 39(2):183-195. PubMed ID: 28287881
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of enalapril and irbesartan in experimental papillary necrosis.
Garber SL; Mirochnik Y; Arruda JA; Dunea G; Slobodskoy L
Kidney Blood Press Res; 2001; 24(1):39-43. PubMed ID: 11174005
[TBL] [Abstract][Full Text] [Related]
19. Urinary transforming growth factor-beta (TGF-beta) excretion and renal production of TGF-beta in rats with subtotal renal ablation: effect of enalapril and nifedipine.
Monteiro de Freitas AS; Coimbra TM; Costa RS; Baroni EA
Nephron; 1998; 78(3):302-9. PubMed ID: 9546691
[TBL] [Abstract][Full Text] [Related]
20. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition.
Kon V; Fogo A; Ichikawa I
Kidney Int; 1993 Sep; 44(3):545-50. PubMed ID: 8231026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
